Kasumi Tsukamoto
Tokyo, Japan
Last Updated: 09/26/2026
Save publications for later
Sign Up
Not sure about your diagnosis?
Check Your Symptoms
Found 8 publications
Nintedanib induces rapid remission of steroid-resistant pulmonary fibrosis in an immunocompromised patient with recurrent COVID-19: A case report.
Journal: Respiratory medicine case reports
Published: August 11, 2025
Efficacy and Safety of First-Line Nivolumab Plus Ipilimumab in Patients with Postoperative Recurrent and Inoperable Non-Small Cell Lung Cancer: A Real-World Retrospective Observational Study.
Journal: Medicina (Kaunas, Lithuania)
Published: March 21, 2025
Alternating Administration of Osimertinib for Leptomeningitis and Docetaxel Plus Ramucirumab for Lung Adenocarcinoma Resistant to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors.
Journal: Internal medicine (Tokyo, Japan)
Published: December 25, 2024
Efficacy and safety of first-line nivolumab plus ipilimumab treatment in elderly patients (aged ≥ 75 years) with non-small cell lung cancer.
Journal: Journal of cancer research and clinical oncology
Published: December 04, 2024
A Real-Word Analysis of the Correlation Between Clinical Efficacy and Predictive Factors of Immune-Related Adverse Events in Patients With Nonsmall Lung Cancer Treated With Nivolumab Plus Ipilimumab.
Journal: Cancer medicine
Published: September 30, 2024
False negative results on PCR for SARS-COV-2 using nasopharyngeal swab.
Journal: Infectious diseases (London, England)
Published: March 24, 2021
Showing 1-8 of 8
Last Updated: 09/26/2026